No profile data available.
Actuate Therapeutics, Inc. Common stock (ACTU) is a healthcare company in the additional cancer treatment drugs industry, based in Fort Worth, United States, with about 12 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$22.23 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $14.65 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Actuate Therapeutics, Inc. Common stock reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$14.65 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Allarity Therapeutics, Inc. (ALLR), Pasithea Therapeutics Corp. (KTTA), TScan Therapeutics, Inc. (TCRX), AlphaTON Capital Corp. (ATON).